Shopping Cart 0
Cart Subtotal
AED 0

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium's other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Canton, Massachusetts, the US.

Collegium Pharmaceutical Inc (COLL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Collegium Pharma Raises USD50 Million in Venture Financing 13

Collegium Pharma Raises USD 4 Million In Venture Financing 15

Collegium Pharma Raises USD 22.5 Million In Series B Financing 16

Licensing Agreements 17

Collegium Pharma Enters into Licensing Agreement with Depomed 17

Equity Offering 18

Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18

Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19

Collegium Pharma Raises USD55 Million in Public Offering of Shares 21

Collegium Pharma Raises USD80 Million in IPO 23

Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25

Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26

Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27

Collegium Pharmaceutical Inc-Key Competitors 28

Collegium Pharmaceutical Inc-Key Employees 29

Collegium Pharmaceutical Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 08, 2018: Collegium reports second quarter financial results and provides corporate update 31

May 09, 2018: Collegium Reports First Quarter Financial Results and Provides Corporate Update 2018 33

Mar 07, 2018: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 2017 35

Nov 08, 2017: Collegium Announcers Third Quarter Financial Results and Provides Corporate Update 37

Aug 09, 2017: Collegium Reports Second Quarter Financial Results and Provides Corporate Update 39

May 10, 2017: Collegium Reports 2017 First Quarter Financial Results and Provides Corporate Update 41

Mar 09, 2017: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 42

Corporate Communications 43

Jul 10, 2018: Collegium Promotes Scott Dreyer To CCO 43

Jun 04, 2018: Collegium Promotes Joseph Ciaffoni To Chief Executive Officer 44

May 30, 2017: Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer 45

Product News 46

06/08/2017: Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids 46

06/01/2017: Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients 47

04/03/2017: Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients 48

02/01/2017: Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER 49

Clinical Trials 50

Mar 16, 2017: Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Collegium Pharma Raises USD50 Million in Venture Financing 13

Collegium Pharma Raises USD 4 Million In Venture Financing 15

Collegium Pharma Raises USD 22.5 Million In Series B Financing 16

Collegium Pharma Enters into Licensing Agreement with Depomed 17

Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18

Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19

Collegium Pharma Raises USD55 Million in Public Offering of Shares 21

Collegium Pharma Raises USD80 Million in IPO 23

Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25

Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26

Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27

Collegium Pharmaceutical Inc, Key Competitors 28

Collegium Pharmaceutical Inc, Key Employees 29

Collegium Pharmaceutical Inc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Collegium Pharmaceutical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium's other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Canton, Massachusetts, the US.

Collegium Pharmaceutical Inc (COLL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Collegium Pharma Raises USD50 Million in Venture Financing 13

Collegium Pharma Raises USD 4 Million In Venture Financing 15

Collegium Pharma Raises USD 22.5 Million In Series B Financing 16

Licensing Agreements 17

Collegium Pharma Enters into Licensing Agreement with Depomed 17

Equity Offering 18

Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18

Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19

Collegium Pharma Raises USD55 Million in Public Offering of Shares 21

Collegium Pharma Raises USD80 Million in IPO 23

Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25

Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26

Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27

Collegium Pharmaceutical Inc-Key Competitors 28

Collegium Pharmaceutical Inc-Key Employees 29

Collegium Pharmaceutical Inc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Aug 08, 2018: Collegium reports second quarter financial results and provides corporate update 31

May 09, 2018: Collegium Reports First Quarter Financial Results and Provides Corporate Update 2018 33

Mar 07, 2018: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 2017 35

Nov 08, 2017: Collegium Announcers Third Quarter Financial Results and Provides Corporate Update 37

Aug 09, 2017: Collegium Reports Second Quarter Financial Results and Provides Corporate Update 39

May 10, 2017: Collegium Reports 2017 First Quarter Financial Results and Provides Corporate Update 41

Mar 09, 2017: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 42

Corporate Communications 43

Jul 10, 2018: Collegium Promotes Scott Dreyer To CCO 43

Jun 04, 2018: Collegium Promotes Joseph Ciaffoni To Chief Executive Officer 44

May 30, 2017: Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer 45

Product News 46

06/08/2017: Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids 46

06/01/2017: Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients 47

04/03/2017: Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients 48

02/01/2017: Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER 49

Clinical Trials 50

Mar 16, 2017: Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Collegium Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Collegium Pharma Raises USD50 Million in Venture Financing 13

Collegium Pharma Raises USD 4 Million In Venture Financing 15

Collegium Pharma Raises USD 22.5 Million In Series B Financing 16

Collegium Pharma Enters into Licensing Agreement with Depomed 17

Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18

Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19

Collegium Pharma Raises USD55 Million in Public Offering of Shares 21

Collegium Pharma Raises USD80 Million in IPO 23

Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25

Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26

Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27

Collegium Pharmaceutical Inc, Key Competitors 28

Collegium Pharmaceutical Inc, Key Employees 29

Collegium Pharmaceutical Inc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Collegium Pharmaceutical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.